Elanco Animal Health Incorporated $ELAN Holdings Trimmed by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,771,254 shares of the company’s stock after selling 188,630 shares during the quarter. Bank of New York Mellon Corp owned about 0.36% of Elanco Animal Health worth $25,294,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ELAN. Envestnet Asset Management Inc. raised its holdings in shares of Elanco Animal Health by 26.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 268,791 shares of the company’s stock worth $2,822,000 after purchasing an additional 56,887 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after buying an additional 2,090 shares in the last quarter. Xponance Inc. lifted its position in shares of Elanco Animal Health by 8.4% during the 1st quarter. Xponance Inc. now owns 24,415 shares of the company’s stock valued at $256,000 after acquiring an additional 1,891 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Elanco Animal Health by 1.5% during the 1st quarter. New York State Common Retirement Fund now owns 280,065 shares of the company’s stock worth $2,941,000 after acquiring an additional 4,209 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Elanco Animal Health by 138.8% during the 1st quarter. Victory Capital Management Inc. now owns 271,338 shares of the company’s stock worth $2,849,000 after acquiring an additional 157,708 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $21.09 on Friday. The company has a market capitalization of $10.48 billion, a PE ratio of 351.49, a PEG ratio of 2.99 and a beta of 1.71. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The company’s 50 day moving average price is $20.59 and its 200 day moving average price is $16.61. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $23.09.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the business posted $0.13 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ELAN shares. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Piper Sandler raised their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 11th. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Thursday. Finally, UBS Group raised their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.